{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-056887","form_type":"8-K","ticker":"BTAI","cik":"0001720893","company_name":"BioXcel Therapeutics, Inc.","filed_at":"2023-05-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:40.219513+00:00","generated_at":"2026-06-15T13:47:38.781323+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"BioXcel Therapeutics Q1 net loss $52.8M; IGALMI formulary wins double to 130","bullets":["Net revenue ~$206K for Q1 2023; net loss of $52.8M vs $31.5M YoY.","Cash $165.5M; cash runway into 2025 with Oaktree/QIA financing and IGALMI revenues.","IGALMI: 130 formulary wins (doubled in 2 months); $55M market unlocked, $255M scheduled for vote.","Key pipeline data expected: SERENITY III (May 2023), TRANQUILITY II (June 2023), MDD Phase 1b (May 2023).","R&D expenses $27.8M (+49% YoY); SG&A $23.6M (+83% YoY) driven by IGALMI launch."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-056887","json":"https://secwatch.observer/filing/0001104659-23-056887.json","markdown":"https://secwatch.observer/filing/0001104659-23-056887.md","text":"https://secwatch.observer/filing/0001104659-23-056887.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1720893/000110465923056887/0001104659-23-056887-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1720893/000110465923056887/tm239728d5_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T13:47:38.781323+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0a0e4614fb61d699be08d47d99715cb7cfb59a44","claim":"BioXcel Therapeutics, Inc. reported financial results for three months ended March 31, 2023.","evidence_excerpt":"On May 8, 2023, BioXcel Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the three months ended March 31, 2023 and provided a business update.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1720893/000110465923056887/0001104659-23-056887-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"three months ended March 31, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}